Natixis Moderna, Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Moderna, Inc. stock. As of the latest transaction made, Natixis holds 64,013 shares of MRNA stock, worth $2.53 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

64,013

Previous 246,806 74.06%

Holding current value

$2.53 Million

Previous $29.3 Million 85.41%

% of portfolio

0.02%

Previous 0.17%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$63.64 - $125.14 $11.6 Million - $22.9 Million	-182,793 Reduced 74.06%	64,013 $4.28 Million
Q2 2024 Aug 13, 2024	BUY	$101.21 - $166.61 $25 Million - $41.1 Million	246,806 New	246,806 $29.3 Million
Q4 2023 Feb 13, 2024	BUY	$69.51 - $104.43 $3.24 Million - $4.87 Million	46,649 Added 1495.16%	49,769 $4.95 Million
Q3 2023 Nov 14, 2023	SELL	$96.41 - $126.61 $717,676 - $942,484	-7,444 Reduced 70.47%	3,120 $322,000
Q2 2023 Aug 11, 2023	BUY	$118.5 - $160.53 $870,264 - $1.18 Million	7,344 Added 228.07%	10,564 $1.28 Million
Q1 2023 May 12, 2023	BUY	$135.66 - $197.02 $436,825 - $634,404	3,220 New	3,220 $494,000
Q4 2022 Feb 13, 2023	SELL	$118.38 - $210.04 $3.37 Million - $5.99 Million	-28,496 Reduced 18.49%	125,628 $22.6 Million
Q3 2022 Nov 14, 2022	SELL	$118.07 - $194.18 $9.24 Million - $15.2 Million	-78,280 Reduced 33.68%	154,124 $18.7 Million
Q2 2022 Aug 12, 2022	BUY	$117.13 - $176.59 $20.6 Million - $31.1 Million	176,223 Added 313.67%	232,404 $33.2 Million
Q1 2022 May 13, 2022	SELL	$126.46 - $235.05 $14.5 Million - $27 Million	-114,692 Reduced 67.12%	56,181 $9.68 Million
Q4 2021 Feb 14, 2022	SELL	$225.82 - $368.51 $35 Million - $57.1 Million	-154,813 Reduced 47.53%	170,873 $43.4 Million
Q3 2021 Nov 12, 2021	BUY	$221.9 - $484.47 $15.8 Million - $34.5 Million	71,169 Added 27.96%	325,686 $125 Million
Q2 2021 Aug 13, 2021	SELL	$129.91 - $234.98 $61.8 Million - $112 Million	-475,857 Reduced 65.15%	254,517 $59.8 Million
Q1 2021 May 14, 2021	BUY	$109.18 - $185.98 $37.2 Million - $63.3 Million	340,465 Added 87.32%	730,374 $95.6 Million
Q4 2020 Feb 12, 2021	BUY	$65.74 - $169.86 $20.5 Million - $53.1 Million	312,416 Added 403.15%	389,909 $40.7 Million
Q3 2020 Nov 12, 2020	SELL	$54.34 - $94.85 $9.52 Million - $16.6 Million	-175,181 Reduced 69.33%	77,493 $5.48 Million
Q2 2020 Aug 13, 2020	BUY	$29.67 - $80.0 $7.5 Million - $20.2 Million	252,674 New	252,674 $16.2 Million
Q4 2019 Feb 14, 2020	SELL	$13.93 - $21.28 $346,968 - $530,042	-24,908 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$12.26 - $18.07 $52,264 - $77,032	4,263 Added 20.65%	24,908 $397,000
Q2 2019 Aug 13, 2019	SELL	$13.7 - $28.34 $150,371 - $311,059	-10,976 Reduced 34.71%	20,645 $302,000
Q1 2019 May 15, 2019	BUY	$14.45 - $23.7 $456,923 - $749,417	31,621 New	31,621 $622,000

Others Institutions Holding MRNA

# of Institutions

953

Shares Held

240M

Call Options Held

10.6M

Put Options Held

18.7M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $15.5B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account